Belluscura PLC (GB:BELL) has released an update.
Belluscura PLC, a medical device developer, announces substantial progress and a positive outlook with its oxygen enrichment technologies, X-PLOR and DISCOV-R. Sales in the first half of 2024 have doubled each month, with May sales hitting $450k, and the company is preparing for the full commercial launch of DISCOV-R in the second half of 2024. Despite a loss before tax of $18.5m for the year ended 2023, the company anticipates strong growth in the coming years, bolstered by strategic expansions in the US and China and approvals to sell in additional Asian markets.
For further insights into GB:BELL stock, check out TipRanks’ Stock Analysis page.
